Anirban Maitra, Laura and Isaac Perlmutter Professor of Pathology and Director of the Perlmutter Cancer Center, shared on LinkedIn:
”As the first panRAS inhibitor marches towards approval, NYU Langone Health own Paul Oberstein – who was part of the pivotal phase 3 study – talks about this trial and the future of pancreatic cancer therapy.
Lots to discuss in this episode of ‘The Moonlight Shif’ ”
Title: RASolute 302 and the Future of Pancreatic Cancer Treatment: Paul Oberstein, MD, on the KRAS Breakthrough
Authors: Gina Mauro, Paul Oberstein
Other articles about pancreatic cancer on OncoDaily.